News
NEO
16.39
+6.50%
1.00
NeoGenomics To Present Four Studies At AMP 2024 Showcasing ctDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment
Benzinga · 4d ago
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Barchart · 4d ago
Weekly Report: what happened at NEO last week (1111-1115)?
Weekly Report · 5d ago
Life sciences stocks viewed positively at TD Cowen despite post-election weakness
Seeking Alpha · 11/15 20:55
FELICIA WILLIAMS JOINS NEOGENOMICS BOARD OF DIRECTORS
Reuters · 11/14 13:10
Earnings Scheduled For November 14, 2024
Benzinga · 11/14 08:32
Weekly Report: what happened at NEO last week (1104-1108)?
Weekly Report · 11/11 11:19
NeoGenomics: Strong Growth Potential in Oncology Lab Testing Justifies Buy Rating
TipRanks · 11/07 07:06
Analysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), NeoGenomics (NEO)
TipRanks · 11/06 12:20
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 11/06 12:02
NeoGenomics: Balancing Growth in NGS with ADx Challenges Amid Strategic Progress
TipRanks · 11/06 10:18
NeoGenomics Price Target Maintained With a $19.00/Share by Needham
Dow Jones · 11/06 10:15
Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
Benzinga · 11/06 10:06
Neogenomics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/06 04:53
NeoGenomics Reports Strong Q3 2024 Growth
TipRanks · 11/06 04:02
Based on the provided financial report, the title of the article is: "NEOGENOMICS, INC. (Form 10-Q)
Press release · 11/05 23:05
NeoGenomics’ Strong Q3 Performance and Growth Potential Drive Buy Recommendation
TipRanks · 11/05 21:45
NeoGenomics’ Strong Financial Performance and Growth Potential Earns Buy Rating
TipRanks · 11/05 16:35
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say
NASDAQ · 11/05 15:00
Morning Movers: GlobalFoundries and Apollo Global gain following Q3 results
TipRanks · 11/05 14:01
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.